Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents (2019 - 2025)

BridgeBio Pharma's Cash & Equivalents history spans 7 years, with the latest figure at $643.0 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 141.42% year-over-year to $643.0 million; the TTM value through Sep 2025 reached $643.0 million, up 141.42%, while the annual FY2024 figure was $359.8 million, 4.3% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $643.0 million at BridgeBio Pharma, down from $749.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $749.0 million in Q2 2025 and bottomed at $180.3 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $400.6 million (2021), against an average of $423.2 million.
  • The largest annual shift saw Cash & Equivalents crashed 50.85% in 2021 before it soared 167.95% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $393.8 million in 2021, then dropped by 4.34% to $376.7 million in 2022, then decreased by 0.2% to $375.9 million in 2023, then dropped by 4.3% to $359.8 million in 2024, then soared by 78.71% to $643.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Cash & Equivalents are $643.0 million (Q3 2025), $749.0 million (Q2 2025), and $359.8 million (Q4 2024).